Caris Life Sciences, Inc.
$21.24
▲
0.84%
2026-04-21 05:52:01
www.carislifesciences.com
NMS: CAI
Explore Caris Life Sciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.98 B
Current Price
$21.24
52W High / Low
$42.5 / $16.28
Stock P/E
—
Book Value
$2.04
Dividend Yield
—
ROCE
4.52%
ROE
-45.37%
Face Value
—
EPS
$-3.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1,846
Beta
—
Debt / Equity
74.08
Current Ratio
7.85
Quick Ratio
7.35
Forward P/E
48.85
Price / Sales
6.28
Enterprise Value
$4.73 B
EV / EBITDA
69.83
EV / Revenue
5.82
Rating
Strong Buy
Target Price
$31.91
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Omeros Corporation | $13.47 | — | $997.87 M | — | -49.6% | 2.21% | $17.65 / $2.95 | $-1.69 |
| 2. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 3. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 4. | Canton Strategic Holdings, Inc. | $3.51 | — | $194.33 M | — | -3.9% | -17.99% | $9.08 / $1.05 | $10.72 |
| 5. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 6. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 7. | Olema Pharmaceuticals, Inc. | $16.58 | — | $1.47 B | — | -37.1% | -36.61% | $36.26 / $3.89 | $5.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|
| Sales | 292.89 M | 216.83 M | 181.4 M | 120.92 M |
| Operating Profit | 88.41 M | 32.64 M | -17.99 M | -57.95 M |
| Net Profit | 81.96 M | 24.32 M | -71.79 M | -102.58 M |
| EPS in Rs | 0.29 | 0.09 | -0.25 | -0.36 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 812.03 M | 412.26 M | 306.13 M | 258.49 M |
| Operating Profit | 45.11 M | -257.12 M | -319.55 M | -315.76 M |
| Net Profit | -68.09 M | -281.89 M | -341.42 M | -320.83 M |
| EPS in Rs | -0.24 | -1 | -1.21 | -1.14 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.13 B | 343.73 M | 412.9 M | 717.42 M |
| Total Liabilities | 548.36 M | 2.84 B | 2.56 B | 2.42 B |
| Equity | 577.31 M | -2.5 B | -2.14 B | -1.7 B |
| Current Assets | 997.8 M | 215.73 M | 242.61 M | 516.04 M |
| Current Liabilities | 127.14 M | 165.42 M | 95.14 M | 136.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 83.16 M | -245.2 M | -276.1 M | -285.71 M |
| Investing CF | -16.26 M | 52.93 M | 214.77 M | -282.99 M |
| Financing CF | 664.99 M | 200.29 M | 10.13 M | 10.45 M |
| Free CF | 66.89 M | -253.64 M | -298.42 M | -327.96 M |
| Capex | -16.26 M | -8.44 M | -22.32 M | -42.26 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 96.97% | 34.67% | 18.43% | — |
| Earnings Growth % | 75.85% | 17.43% | -6.42% | — |
| Profit Margin % | -8.38% | -68.38% | -111.53% | -124.12% |
| Operating Margin % | 5.56% | -62.37% | -104.38% | -122.16% |
| Gross Margin % | 66.4% | 43.37% | 29.17% | 30.96% |
| EBITDA Margin % | 1.4% | -44.38% | -85.19% | -95.13% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.